Quince Therapeutics Files Administrative 8-K on Dec 29, 2023 Event

TL;DR

**Quince Therapeutics filed a routine 8-K, no major news here.**

AI Summary

Quince Therapeutics, Inc. filed an 8-K on January 3, 2024, reporting an "Other Events" item that occurred on December 29, 2023. This filing primarily updates the company's registration information, including its address at 611 Gateway Blvd., Suite 273, South San Francisco, California, 94080, and confirms its Delaware incorporation. For investors, this filing is largely administrative and does not disclose new financial results, strategic shifts, or material operational changes that would directly impact the stock's valuation.

Why It Matters

This filing is largely administrative, updating basic company information, and does not contain new material financial or operational news that would typically move the stock.

Risk Assessment

Risk Level: low — The filing is administrative and does not introduce new financial risks or operational uncertainties.

Analyst Insight

A smart investor would note this filing is administrative and not indicative of any immediate change in the company's financial health or strategic direction, thus requiring no immediate action based solely on this 8-K.

Key Players & Entities

• Quince Therapeutics, Inc. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Quince Therapeutics, Inc.
• 611 Gateway Boulevard, Suite 273 (company) — address of principal executive offices for Quince Therapeutics, Inc.
• South San Francisco, California (company) — city and state of principal executive offices for Quince Therapeutics, Inc.
• 94080 (company) — zip code of principal executive offices for Quince Therapeutics, Inc.
• December 29, 2023 (date) — date of the earliest event reported in the 8-K
• January 3, 2024 (date) — date the 8-K was filed

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share QNCX The Nasdaq Stock Mar
• $1.00 — e Company's common stock had been below $1.00 per share for the previous 30 consecuti

Filing Documents

• d641060d8k.htm (8-K) — 25KB
• 0001193125-24-001482.txt ( ) — 178KB
• qncx-20231229.xsd (EX-101.SCH) — 4KB
• qncx-20231229_def.xml (EX-101.DEF) — 13KB
• qncx-20231229_lab.xml (EX-101.LAB) — 22KB
• qncx-20231229_pre.xml (EX-101.PRE) — 14KB
• d641060d8k_htm.xml (XML) — 5KB

01

Item 8.01 Other Events As previously reported, on December 4, 2023, Quince Therapeutics, Inc. (the "Company") received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that the closing bid price of the Company's common stock had been below $1.00 per share for the previous 30 consecutive business days, and that, as a result, the Company was not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the "Rule"). The Company was provided 180 calendar days, until June 3, 2024, to regain compliance. On December 29, 2023, the Company received written notice from the Listing Qualifications Department of Nasdaq notifying the Company that, for the last 13 consecutive business days, from December 11, 2023 through December 28, 2023, the closing bid price of the Company's common stock was $1.00 per share or greater. Accordingly, the written notice stated that the Company has regained compliance with the minimum bid price listing requirement set forth under the Rule and that the matter was now closed. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Quince Therapeutics, Inc. By: /s/ Dirk Thye Date: January 3, 2024 Name: Dirk Thye Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR